Gapping up
In reaction to earnings/guidance:
- TLRY +6.4%, NSTG +5.3%, NVTA +2.9%, EXAS +2.4%, TSM +1.8%, HOLX +1.7%, NVRO +1.7%, ALNY +1.2%, OSW +1.1%, CMC +1%, FIGS +1%, WEC +0.8%, ASX +0.8%
Other news:
- ZNGA +51.7% (Zynga and Take-Two (TTWO) to merge in cash and stock deal which values the total enterprise at approx. $12.7 bln)
- APR +24.6% ( to be acquired by Owens & Minor (OMI) for $37.50/share in cash)
- MOLN +21.7% (Molecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19 )
- IPSC +12.1% (Century Therapeutics and Bristol-Myers (BMY) enter collaboration agreement to develop iPSC-derived allogeneic cell therapies)
- DNAY +8.3% (strategic collaboration and licensing agreement with Pfizer)
- OCGN +6.9% (reports COVAXIN booster dose study demonstrates robust immune responses and long-term safety)
- SWAV +6.4% (received takeover interest according to Bloomberg)
- BMRN +5.6% (Announces Stable and Durable Annualized Bleed Control in the Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at Two Year Analysis)
- ORTX +5.5% (Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones)
- BEAM +4.9% (Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones; Beam Therapeutics and Pfizer (PFE) enter exclusive multi-target research collaboration to advance novel in vivo base editing programs for a range of rare diseases)
- SDC +2.8% (CFO Kyle Wailes to step down)
- HGEN +2.2% (aligns with FDA on potential registration phase 3 study for lenzilumab with CAR-T)
- PTRA +1.9% (Postive Barrons article)
- CVAC +1.6% (publishes timeline for several program)
Analyst comments:
- INFY +2.4% (upgraded to Positive from Neutral at Susquehanna)
- GOSS +2.3% (upgraded to Outperform from Neutral at SMBC Nikko)
- H +2% (upgraded to Buy from Underperform at BofA Securities)
- AR +1.2% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- GNRC +1.2% (upgraded to Buy from Neutral at UBS)